"The
Report PharmaPoint: Rheumatoid Arthritis - US Drug Forecast and
Market Analysis to 2023 provides information on pricing, market
analysis, shares, forecast, and company profiles for key industry
participants. - MarketResearchReports.biz"
Description
PharmaPoint: Rheumatoid
Arthritis - US Drug Forecast and Market Analysis to 2023
Summary
Rheumatoid arthritis (RA) is a
chronic autoimmune disease which causes inflammation and deformity of
the joints. It affects over seven million individuals in the 10MM
covered in this report (US, France, Germany, Italy, Spain, UK, Japan,
Australia, China, and India) and the prevalence is expected to grow
to just over 8.5 million individuals by 2023. The anti-TNFs have been
effective in treating the signs and symptoms of RA and inhibiting
progression to erosive bone disease. However, the landscape is
quickly changing with the introduction of biosimilars, novel
biologics, and a class of oral therapies known as JAK inhibitors, all
of which will change the market dynamics between 2013 and 2023. With
the anti-TNFs as extremely effective therapies for RA, the market is
extremely competitive for new entrants and will undergo further
pressure as biosimilars are approved and launch.
This market will be driven
heavily by the increased population of RA patients, due, in part, to
the growing overall population, an increased life expectancy, and
increased awareness of RA, which requires early diagnosis and
treatment. In addition, changes in healthcare resulting from
implementation of the Affordable Care Act (ACA) will mean that access
to physicians and pharmaceuticals will increase over the forecast
period.
View Full Report at
http://www.marketresearchreports.biz/analysis/247056
Scope
- Overview of Rheumatoid
arthritis including epidemiology, etiology, symptoms, diagnosis,
pathology and treatment guidelines as well as an overview on the
competitive landscape.
- Detailed information on the
key drugs in the US including product description, safety and
efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top
drugs in the US from 2013-2023.
- Analysis of the impact of
key events as well the drivers and restraints affecting the US
Rheumatoid arthritis market.
Reasons
to buy
- Understand and capitalize by
identifying products that are most likely to ensure a robust return
- Stay ahead of the
competition by understanding the changing competitive landscape for
Rheumatoid arthritis
- Effectively plan your M&A
and partnership strategies by identifying drugs with the most
promising sales potential
- Make more informed business
decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for
drugs from 2013-2023 in the US
Download
Detail Report With Complete TOC at
Table
of Content
1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 9
1.2 List of Figures 13
2 Introduction 14
2.1 Catalyst 14
2.2 Related Reports 15
2.3 Upcoming Related Reports 18
3 Disease Overview 19
3.1 Etiology and Pathophysiology 19
3.1.1 Etiology 19
3.1.2 Pathophysiology 19
3.2 Symptoms 24
3.3 Prognosis 25
3.4 Quality of Life 25
4 Disease Management 26
4.1 Diagnosis and Treatment Overview 26
4.1.1 Diagnosis 26
4.1.2 Treatment Guidelines 28
4.1.3 Leading Prescribed Drugs for the Treatment of RA 36
4.1.4 Clinical Practice 37
4.2 US 41
5 Competitive Assessment 46
5.1 Overview 46
5.2 Product Profiles - Major Brands 47
5.2.1 Enbrel (etanercept) 47
5.2.2 Humira (adalimumab) 53
5.2.3 Remicade (infliximab) 56
5.2.4 Simponi (golimumab) 61
5.2.5 Cimzia (certolizumab pegol) 66
5.2.6 Orencia (abatacept) 70
5.2.7 Actemra/RoActemra (tocilizumab) 75
Browse
Latest News at http://www.marketresearchreports.biz/articles
About
Us
MarketResearchReports.biz is
the most comprehensive collection of market research reports.
MarketResearchReports.Biz services are specially designed to save
time and money for our clients. We are a one stop solution for all
your research needs, our main offerings are syndicated research
reports, custom research, subscription access and consulting
services. We serve all sizes and types of companies spanning across
various industries.
Browse
Our Press Releases by Prnewswire:
http://www.prnewswire.com/news/marketresearchreports.biz
Contact
Us
Office:
State Tower
90 Sate Street, Suite 700
Albany, NY 12207
United States
Tel: +1-518-618-1030
USA: Canada Toll Free:
866-997-4948
No comments:
Post a Comment